Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Diabetes Mellitus, Type 2 1 Cushing Syndrome 1 ACTH Syndrome, Ectopic 1

Interventions

pembrolizumab 302 Carboplatin 230 Cisplatin 159 Paclitaxel 153 Gemcitabine 153 Pemetrexed 122 Bevacizumab 121 Docetaxel 105 durvalumab 83 Oxaliplatin 82 Nivolumab 82 Dexamethasone 80 atezolizumab 79 Fluorouracil 79 Cyclophosphamide 79 130-nm albumin-bound paclitaxel 74 Fulvestrant 72 Capecitabine 67 Injections 66 Cetuximab 64 Leucovorin 63 Rituximab 57 fludarabine 52 Lenalidomide 51 venetoclax 47 Prednisone 45 Irinotecan 42 enzalutamide 41 Letrozole 41 tislelizumab 38

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × ASP3662 × 90 days × Clear all

NCT07296484 2026-05-12

CAPTAIN-T2D

Sparrow Pharmaceuticals

Phase 2 Recruiting

ACTH Syndrome, Ectopic, Cushing Syndrome, Diabetes Mellitus, Type 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡